secwatch.observer — SEC 8-K summary
======================================

Issuer:     Maze Therapeutics, Inc. (MAZE)
CIK:        0001842295
Form:       8-K
Filed at:   2026-06-10T20:15:18+00:00
Accession:  0001193125-26-265858
Event type: other
Sentiment:  neutral
Materiality: 0.10
Item codes: 5.07
LLM model:  deepseek-v4-flash:cloud@v2

Maze Therapeutics shareholders re-elect two directors, ratify auditor at 2026 annual meeting
--------------------------------------------------------------------------------

- Quorum of 44,660,029 shares (89.75% of outstanding) present at June 8 meeting.
- Jason Coloma re-elected with 35,792,536 votes for, 5,926,467 withheld.
- Neil Kumar re-elected with 34,056,425 votes for, 7,662,578 withheld.
- Ratification of Ernst & Young as auditor passed: 44,557,778 for, 728 against.
- No broker non-votes on auditor ratification; 2,941,026 broker non-votes on director election.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1842295/000119312526265858/0001193125-26-265858-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1842295/000119312526265858/d110541d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-265858

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer